BioSpace News Archive

RadNet, Inc., a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced that it will host a conference call to discuss its second quarter 2021 financial results on Monday, August 9th, 2021 at 7:30 a.m. Pacific Time.

TherapeuticsMD, Inc. today announced that it will report its second quarter 2021 financial results on Wednesday, August 4, 2021, before the opening of the U.S. financial markets.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced the expansion of its Board of Directors, appointing two new board members, Elizabeth Kwo, MD and Kevin Hobert, effective immediately.

Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that the first COVID-19 patient has been enrolled in the NIH-funded ACTIV-4 Host Tissue trial.

CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients, announced the enrollment of the first patient in the Assessing Chimerism and Relapse of Bone marrow/ HCT transplant using AlloHeme Testing study at the Cleveland Clinic in Ohio.

Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare, a Canadian focused, healthcare company with global reach and a diversified portfolio of commercial products, announced it expects to release its second quarter 2021 financial results before markets open on Monday, August 9, 2021.

MaxCyte, Inc., a leading provider of platform technologies for cell engineering, announced the commencement of an underwritten offering of 12,000,000 shares of common stock at an expected offering price between $11.50 and $13.50 per share.

PDS Biotechnology Corporation will release financial results for the second quarter of 2021 on Thursday, August 12, 2021, before the market opens.

Selecta Biosciences, Inc. today announced the appointment of world renowned AAV gene therapy pioneer Jude Samulski, Ph.D., as a special advisor to assist with the development of their gene therapy programs.

Presentation will highlight the positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating Daré’s product candidate DARE-BV1 in women diagnosed with bacterial vaginosis